Seagen, recently acquired by Pfizer, is a leader in Antibody Drug Conjugates(ADC's)...These are drugs, composed of antibodies,which seek out cancer cells...These antibodies have been linked chemically to cytotoxic compounds, which kill the cancer cells, while preserving normal cells.
This process inevitably produces inflammatory reactions...Vascepa as an anti-inflammatory drug, can ameliorate the consequent inflammation.
Pfizer is going all in on Seagen, having spent 43 billion dollars to do the deal...They might now consider spending considerably less to acquire Vascepa as an adjunct to ADC's...not to mention Vascepa's reduction of CVDs in the aged population, in which cancer is more common.
Market Data 
Markets 
